Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 13/20 | 0.55 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.49 |
| ▸ | BRD2 | P25440 | 2/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498824 | 1.00 | PTGS2 (0.56) | PTGS2PTGS1BRD4EPAS1BRD2 | |
| SCHEMBL15068172 | 0.85 | EPAS1 (0.52) | PTGS2PTGS1BRD4EPAS1 | |
| SCHEMBL20155456 | 0.84 | PTGS2 (0.61) | PTGS2PTGS1BRD4EPAS1BRD2 | |
| SCHEMBL30306252 | 0.82 | EPAS1 (0.71) | PTGS2PTGS1BRD4EPAS1BRD2 | |
| SCHEMBL16651328 | 0.82 | EPAS1 (0.71) | PTGS2PTGS1BRD4EPAS1BRD2 | |
| SCHEMBL15067648 | 0.82 | PTGS2 (0.56) | PTGS2PTGS1BRD4EPAS1BRD2 | |
| SCHEMBL30693774 | 0.79 | HSPB1 (0.67) | PTGS2PTGS1BRD4BRD2BRD3 | |
| SCHEMBL15067482 | 0.79 | HSPB1 (0.67) | PTGS2PTGS1BRD4BRD2BRD3 | |
| SCHEMBL30498839 | 0.78 | PTGS2 (0.46) | PTGS2PTGS1BRD4EPAS1SLC6A4 | |
| SCHEMBL9656894 | 0.78 | PTGS2 (0.58) | PTGS2PTGS1BRD4EPAS1BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109132-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | DESIGN THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4460302-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240124491-A1 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. | 2024-04-18 | — | — | US | disclosed |
| EP-4274583-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023133284-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133284-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2022150555-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150555-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| US-20160185769-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| EP-3013828-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-3013827-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2014206345-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014206150-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124491-A1 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, ATXN2L, CDR2 | PTGS2 3557/4885PTGS1 3878/4885BRD4 742/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | PTGS2 1807/4885PTGS1 450/4885BRD4 1/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | PTGS2 1807/4885PTGS1 450/4885BRD4 1/4885 |
| US-20250109132-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, ATXN2L, ATXN10 | PTGS2 3641/4885PTGS1 3864/4885BRD4 620/4885 |
| US-20160185769-A1 | Bromodomain Inhibitors | BRD1, BRD4, BRD3 | PTGS2 2097/4885PTGS1 401/4885BRD4 2/4885 |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | PTGS2 1807/4885PTGS1 450/4885BRD4 1/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | PTGS2 1807/4885PTGS1 450/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.